Blog

  • Unusual Machines Appoints Jason Reels as Vice President of Supply Chain

    Reels to strengthen operational execution and expand U.S.-based manufacturing capacity for defense and enterprise markets

    ORLANDO, FLORIDA / ACCESS Newswire / October 20, 2025 / Unusual Machines (NYSE AMERICAN:UMAC), a leading provider of NDAA-compliant drone components, today announced the appointment of Jason Reels as Vice President of Supply Chain. Reels will report to Chief Operating Officer Andrew Camden and lead Unusual Machines’ global supply chain operations as the company expands production capacity across its U.S. facilities.

    Reels will oversee inbound logistics, materials management, and fulfillment to improve speed, coordination, and throughput as the company scales motor and headset production to meet growing defense and enterprise demand.

    “Operating a disciplined and efficient supply chain is the backbone of our ability to deliver,” said Andrew Camden, COO of Unusual Machines. “Jason’s experience leading complex logistics networks and scaling production across multiple regions will strengthen our execution as we continue expanding domestic manufacturing.”

    Reels brings more than 15 years of experience across the automotive, manufacturing, and technology sectors, building multi-site supply chains in North America, Mexico, and Asia, and implementing ERP and warehouse systems aligned with NetSuite. His background supports Unusual Machines’ continued emphasis on reliability, compliance, and speed within its production network.

    “We’re building for scale in a way that keeps control and quality front and center,” said Jason Reels. “I’m focused on building the systems and teams that keep production moving at the speed our customers have come to expect from Unusual Machines.”

    About Unusual Machines

    Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032.

    For more information, please visit www.unusualmachines.com.

    Investor Contact

    CS Investor Relations
    investors@unusualmachines.com

    Media Contact

    media@unusualmachines.com

    SOURCE: Unusual Machines, Inc.

    View the original press release on ACCESS Newswire

  • Geotechnical Drilling Starts at Central Gawler Mill

    Geotechnical Drilling Starts at Central Gawler Mill

    Results to inform detailed TSF1 mine design, schedule and costs

    ADELAIDE, AU / ACCESS Newswire / October 22, 2025 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or the Company) is pleased to confirm that geotechnical drilling has started in support of a recently launched Definitive Feasibility Study for ‘Stage 1′ production (Stage 1 DFS) at the Company’s South Australian Challenger Gold Project (Challenger).1

    The planned program includes 5 sonic drilling holes to recover TSF1 materials for laboratory testing, 24 holes for Cone Penetration Testing (CPTu) and further laboratory testing, and 3 holes for push tube density testing.

    The program is expected to take three weeks to complete, with the results to inform the dry recovery of TSF1 tailings materials, detailed mine design, a mining schedule and estimate of mining costs for the Stage 1 DFS.

    Figure 1 – Cross section showing higher-grade peripheral TSF1 materials & 0.7g/t Au grade shell1

    Commenting on the start of geotechnical drilling, Barton Managing Director Alexander Scanlon said:

    “With the Stage 1 DFS now underway, we are excited to kick off the first of several production-related work programs that will inform key elements of mine design, scheduling, equipment selection and operating costs for tailings recovery.

    “Following a $15m placement led by Franklin Templeton, Barton is well funded to advance the restart of operations at its Central Gawler Mill, with approximately $20m cash in the bank and credit financing discussions underway.

    “We are now on the road to production, leveraging our fully permitted Central Gawler Mill to operations and growth. This is an invaluable stepping stone for our vision to become South Australia’s largest independent gold producer.”

    Authorised by the Managing Director of Barton Gold Holdings Limited.

    For further information, please contact:

    Alexander Scanlon
    Managing Director
    a.scanlon@bartongold.com.au
    +61 425 226 649

    Jade Cook
    Company Secretary
    cosec@bartongold.com.au
    +61 8 9322 1587

    About Barton Gold
    Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 2.2Moz Au & 3.1Moz Ag JORC Mineral Resources (79.9Mt @ 0.87g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

    Challenger Gold Project

    • 313koz Au + fully permitted Central Gawler Mill (CGM)

    Tarcoola Gold Project

    • 20koz Au in fully permitted open pit mine near CGM

    • Tolmer discovery grades up to 84g/t Au & 17,600g/t Ag

    Tunkillia Gold Project

    • 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources

    • Competitive 120kozpa gold & 250kozpa silver project

    Wudinna Gold Project

    • 279koz Au project located southeast of Tunkillia

    • Significant optionality, adjacent to main highway

    Competent Persons Statement & Previously Reported Information

    The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

    Activity

    Competent Person

    Membership

    Status

    Tarcoola Mineral Resource (Stockpiles)

    Dr Andrew Fowler (Consultant)

    AusIMM

    Member

    Tarcoola Mineral Resource (Perseverance Mine)

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Tarcoola Exploration Results (until 15 Nov 2021)

    Mr Colin Skidmore (Consultant)

    AIG

    Member

    Tarcoola Exploration Results (after 15 Nov 2021)

    Mr Marc Twining (Employee)

    AusIMM

    Member

    Tunkillia Exploration Results (until 15 Nov 2021)

    Mr Colin Skidmore (Consultant)

    AIG

    Member

    Tunkillia Exploration Results (after 15 Nov 2021)

    Mr Marc Twining (Employee)

    AusIMM

    Member

    Tunkillia Mineral Resource

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Challenger Mineral Resource (above 215mRL)

    Mr Ian Taylor (Consultant)

    AusIMM

    Fellow

    Challenger Mineral Resource (below 90mRL)

    Mr Dale Sims

    AusIMM / AIG

    Fellow / Member

    Wudinna Mineral Resource (Clarke Deposit)

    Ms Justine Tracey

    AusIMM

    Member

    Wudinna Mineral Resource (all other Deposits)

    Mrs Christine Standing

    AusIMM / AIG

    Member / Member

    The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

    Cautionary Statement Regarding Forward-Looking Information

    This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

    1Refer to ASX announcement dated 29 September 2025

    * Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 8 September 2025. Total Barton JORC (2012) Mineral Resources include 1,049koz Au (39.7Mt @ 0.82 g/t Au) in Indicated category and 1,186koz Au (40.2Mt @ 0.92 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

    SOURCE: Barton Gold Holdings Limited

    View the original press release on ACCESS Newswire

  • Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

    Company to discontinue development of mRNA-1647 in congenital CMV

    Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients

    Company does not anticipate any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028

    CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s investigational cytomegalovirus (CMV) vaccine. The study did not meet its primary efficacy endpoint of preventing CMV infection in seronegative female participants of childbearing age (16-40 years of age). Moderna will discontinue its congenital CMV clinical development program.

    “Today’s announcement is disappointing for families and healthcare professionals who have been eagerly awaiting a CMV vaccine to prevent congenital CMV, a leading infectious cause of birth defects,” said Stéphane Bancel, Chief Executive Officer of Moderna. “The majority of the data from this trial is still forthcoming, and we will share our full results with the scientific community in hopes that our learnings can contribute to the continued pursuit of a CMV vaccine. I am grateful for our dedicated team, our partners at clinical trial sites, and all the trial participants who made this research possible.”

    The Phase 3 trial (NCT05085366) was a randomized, observer-blind, placebo-controlled study. The study included approximately 7,500 women 16-40 years of age from approximately 300 sites across 13 countries, representing the largest trial assessing the efficacy of a CMV vaccine to-date. Vaccine efficacy against primary CMV infection in healthy women was well below the Company’s target, ranging from 6% to 23% depending on the case definition used.

    “We are clearly disappointed by the failure to prevent primary infection because it means there is still no vaccine for the prevention of congenital CMV despite the many decades of work by the field,” said Stephen Hoge, MD, President of Moderna. “CMV does cause significant disease in other contexts, including reactivation of the latent virus in those undergoing bone marrow transplantation, and we will continue to explore the potential of mRNA-1647 to suppress disease associated with reactivation in those high-risk patients through our ongoing Phase 2 study.”

    mRNA-1647 was found to be generally well-tolerated regardless of CMV serostatus, with a safety profile consistent with earlier studies. No safety concerns have been raised by the Data and Safety Monitoring Board. The Company plans to continue its study of mRNA-1647 in bone marrow transplant patients, which is currently in a Phase 2 trial (NCT05683457).

    Moderna does not anticipate any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028. Moderna anticipated minimal initial revenue contribution from mRNA-1647 given necessary investments in market building and launch, and expected the product to be cash-flow negative in 2028.

    About Moderna

    Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.

    Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s 2025 financial guidance and its expectation of achieving breakeven in 2028; and the potential of mRNA-1647 for bone marrow transplant patients and Moderna’s ongoing Phase 2 trial. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

    Moderna Contacts

    Media:

    Chris Ridley
    Head of Global Media Relations
    +1 617-800-3651
    Chris.Ridley@modernatx.com

    Investors:

    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    +1 617-209-5834
    Lavina.Talukdar@modernatx.com

    SOURCE: Moderna, Inc.

    View the original press release on ACCESS Newswire

  • AeroGuard Flight Training Center Partners With U.S. Air Force to Train Future Pilots

    AeroGuard Flight Training Center Partners With U.S. Air Force to Train Future Pilots

    PHOENIX, ARIZONA / ACCESS Newswire / October 22, 2025 / AeroGuard Flight Training Center, a leading provider of flight training with over 25 years’ experience training professional pilots, is excited to announce a new program with the United States Air Force to provide high-quality training for its student pilots. Through this agreement, AeroGuard will provide the initial flight training for Air Force pilots, equipping them with the skills, knowledge, and experience necessary to advance to the next phase of their military aviation careers.

    AeroGuard Selected by U.S. Air Force to Train Future Pilots
    AeroGuard Selected by U.S. Air Force to Train Future Pilots

    Air Force Pilots will train at AeroGuard’s headquarters in Phoenix, Arizona, USA, where they will receive their initial flight training, obtaining their Private Pilot License with Instrument and Multi Engine Ratings. AeroGuard integrates high-quality flight training into every stage of the program, ensuring a smooth transition for pilots to advance to the next phase of their career preparation.

    AeroGuard’s Phoenix, Arizona, campus offers an unparalleled training environment, providing Air Force pilots with 45,000 square feet of campus, over 360 flying days a year, diverse airspace, large standardized fleet, experienced instructors, and expansive practice areas. This ideal flight training environment provides cadets with well-rounded flight experience, instilling the skills they need to become high-quality and confident pilots.

    Joel Davidson, AeroGuard CEO, shared, “AeroGuard is honored and proud to support the United States Air Force in developing its future pilots. Through this partnership, AeroGuard will provide our expertise in initial pilot training for aspiring professional aviators, while the Air Force will receive well-trained pilots fully prepared for their future military roles. Our commitment to safety, excellence, and the highest-quality pilot training seamlessly aligns with the Air Force’s mission, and we look forward to training their student pilots.”

    As a leading flight training provider for airlines and universities across the globe, Air Force pilots at AeroGuard will train in a structured and professional environment, joining future airline pilots from world-leading airlines such as Cathay Pacific, Air New Zealand, and Air India, as well as hundreds of U.S. students training for their own future careers.

    The first class of Air Force Officers is set to start flight training at the end of this month. AeroGuard looks forward to welcoming these officers to campus and preparing them as they grow into successful, skilled, and fully capable pilots for the United States Air Force.

    About AeroGuard Flight Training Center:

    AeroGuard Flight Training Center is a global leader in ab initio flight training with three U.S. campuses that offer accelerated commercial pilot training programs to candidates from all over the world. With a commitment to safety and student success, AeroGuard’s high-quality and career-focused curriculum has established airline-ready cadets for over 25 years with more than one million flight hours of training experience and graduating over 8,000 cadets.

    Contact Information

    James Constable
    Chief Marketing Officer
    jconstable@flyaeroguard.com
    800-322-1526

    .

    SOURCE: Aeroguard Flight Training Center

    View the original press release on ACCESS Newswire

  • Ketamine Therapy for Anxiety and PTSD Highlighted in Resource from Moment of Clarity

    Ketamine Therapy for Anxiety and PTSD Highlighted in Resource from Moment of Clarity

    Huntington Beach, California – October 17, 2025 – PRESSADVANTAGE –

    Moment of Clarity has published a new resource titled “Using Ketamine for Anxiety and PTSD Treatment“, now available on their website. The article examines how ketamine therapy may support patients living with anxiety disorders and post-traumatic stress disorder (PTSD), particularly those who have not found sufficient relief through traditional treatments. The resource aims to provide patients, families, and communities with a clear understanding of where ketamine fits within modern mental health care.

    Anxiety and PTSD are among the most common mental health challenges, often accompanied by symptoms that disrupt sleep, relationships, and daily functioning. Standard therapies such as medication and counseling remain effective for many, but a significant number of patients experience treatment-resistant symptoms. The publication explains how ketamine, administered in controlled clinical settings, interacts with brain receptors linked to mood regulation and may provide rapid symptom relief. Unlike conventional antidepressants that may take weeks to show benefits, ketamine has demonstrated a faster onset in certain patients.

    Ketamine Assisted Therapy for Mental Health Disorders in Huntington Beach, CA

    Research supports these observations. Studies published in JAMA Psychiatry (2019) and clinical reviews from the National Institutes of Health indicate that ketamine can reduce symptoms of depression and trauma-related conditions in some individuals who did not respond to other treatments. However, the article makes clear that while ketamine is FDA-approved as an anesthetic and esketamine (Spravato) is FDA-approved for treatment-resistant depression, the use of ketamine for anxiety and PTSD remains off-label and should only be provided under careful medical supervision.

    For patients in Huntington Beach, California, the resource highlights how ketamine therapy may complement existing services such as group therapy, family counseling, and psychiatric evaluations. By reducing the intensity of acute symptoms, ketamine may allow patients to engage more effectively in talk therapy and skill-building interventions. The article emphasizes that ketamine is not a replacement for these services, but a tool that can strengthen their impact.

    The publication also addresses safety. Administered in licensed medical environments, ketamine therapy is closely monitored to ensure patient well-being. Common side effects, such as dizziness or mild dissociation, are typically temporary and resolve on their own. Medical supervision ensures that dosing is carefully controlled and that patients receive support throughout each session.

    Another focus is the importance of trauma-informed care. Many patients struggling with PTSD also live with co-occurring conditions such as depression or substance use disorders. The article notes that ketamine therapy is most effective when integrated into comprehensive care programs that may also include cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and medication management. This integrative approach reflects a commitment to addressing both the biological and psychological aspects of recovery.

    Moment of Clarity’s resource also acknowledges the stigma that can surround advanced therapies. Some patients hesitate to explore newer treatments due to fear of judgment or misconceptions about them. By providing evidence-informed explanations of ketamine’s role, the publication seeks to normalize the use of innovative therapies alongside established methods, encouraging earlier access to care.

    Continuity of care is another central theme. While ketamine therapy may provide rapid relief, the resource emphasizes that lasting recovery depends on ongoing therapeutic engagement. Patients may begin with ketamine sessions but require continued counseling, family therapy, and psychiatric evaluations to build resilience and maintain progress over time.

    By publishing Using Ketamine for Anxiety and PTSD Treatment, Moment of Clarity reinforces its role as a trusted provider of patient education. The article explains how ketamine therapy works, clarifies its regulatory status, reviews emerging research, and highlights its potential integration into broader treatment plans.

    For individuals in Huntington Beach and the surrounding area seeking reliable information on advanced mental health options, this resource offers balanced, research-based guidance. By combining education with clinical expertise, Moment of Clarity in Huntington Beach helps patients and families explore innovative recovery pathways while maintaining confidence in the safety and effectiveness of their care.

    ###

    For more information about Moment of Clarity Huntington Beach, contact the company here:

    Moment of Clarity Huntington Beach
    Marie Mello
    (949) 403-6740
    marie@momentofclarity.com

  • WhiteSands Releases New Guide Answering: How To Recognize the Early Signs of Vicodin Addiction

    WhiteSands Releases New Guide Answering: How To Recognize the Early Signs of Vicodin Addiction

    CLEARWATER, FL – October 17, 2025 – PRESSADVANTAGE –

    WhiteSands Alcohol & Drug Rehab Clearwater has released a new online resource titled “Understanding the Signs of Vicodin Addiction“, available on their website. The article offers families and patients practical insight into identifying early warning signs of opioid misuse, the risks associated with Vicodin, and the importance of timely access to supervised withdrawal care.

    The publication highlights that Vicodin, a prescription medication often used for pain relief, carries a high potential for dependence when misused. Many people may not recognize the gradual shift from prescribed use to abuse until physical and psychological symptoms are already present. The article outlines key indicators such as behavioral changes, mood swings, and withdrawal effects as important signals that medical attention is necessary. By presenting this information in clear terms, WhiteSands aims to shorten the time between the onset of symptoms and seeking treatment.

    WhiteSands Alcohol & Drug Rehab Clearwater, Addiction Treatment Services

    The resource underscores that opioid addiction is a medical condition, not a personal weakness. Patients who attempt to stop using Vicodin without clinical guidance often encounter intense withdrawal symptoms, including nausea, muscle pain, anxiety, and insomnia. These symptoms can quickly lead to relapse if detox is attempted outside a supervised setting. Drawing on findings from the Substance Abuse and Mental Health Services Administration (SAMHSA), the article explains that medically supported detox programs improve patient safety and increase the likelihood of successful recovery.

    WhiteSands Clearwater emphasizes the importance of supervised detoxification as the foundation for effective addiction treatment. The center provides 24/7 monitoring in medically supported environments, along with access to medication-assisted protocols that ease discomfort and reduce risks during withdrawal. Detox alone, however, is not sufficient for long-term recovery. Once patients stabilize, they are encouraged to transition into comprehensive care programs that address the psychological and behavioral drivers of addiction through inpatient or outpatient therapy, relapse prevention strategies, and long-term recovery planning.

    The article also explains the importance of integrating detox with evidence-based counseling. Detox clears the body of substances, but therapy addresses the underlying issues that fuel addiction. Combining these approaches ensures patients begin recovery with both physical stability and a plan for emotional and mental health support. Research from the National Institute on Drug Abuse (NIDA) is cited, noting that treatment outcomes are stronger when detoxification is followed by structured therapy and ongoing support services.

    Financial accessibility is another factor addressed in the resource. The article highlights the value of treatment programs that strike a balance between affordability and clinical quality, noting that cost concerns often deter families from seeking help. By encouraging patients and their loved ones to explore programs that provide both safety and cost-effective care, WhiteSands aims to reduce the barriers that prevent people from pursuing treatment.

    Local context is acknowledged throughout the publication, with attention given to the needs of Clearwater residents and the surrounding areas. Whether in coastal neighborhoods like Clearwater Beach or smaller nearby communities, the challenges of opioid misuse remain consistent: families often struggle to recognize when prescription use has become dependency, and patients may delay care until the addiction is advanced. The resource seeks to address this gap in awareness by offering guidance that is both medically accurate and accessible to all patients.

    The article concludes by stressing the urgency of early intervention. Delays in addressing Vicodin misuse can lead to worsening dependence, health complications, and increased risk of overdose. By making information available online, WhiteSands aims to reach families at the critical point when questions first arise about whether a loved one may be struggling with opioid misuse.

    For people searching for “drug rehab near me” or “medication-assisted detox in Clearwater,” this resource provides clear, evidence-based information rather than promotional promises. It is designed to help families make informed decisions, emphasizing that recovery begins with recognizing the signs and taking action promptly.

    With the release of Understanding the Signs of Vicodin Addiction, WhiteSands Alcohol & Drug Rehab reinforces its role as both a treatment provider and an educational resource. By focusing on the warning signs of opioid misuse and the importance of supervised detox, the center continues its mission to support patients and families with compassion, clinical expertise, and a commitment to long-term recovery.

    ###

    For more information about WhiteSands Alcohol & Drug Rehab Clearwater, contact the company here:

    WhiteSands Alcohol & Drug Rehab Clearwater
    Ryan Monesson
    (727) 270-9970
    rmonesson@wstreatment.com
    1932 Drew St, Clearwater, FL 33765

  • SMX Tightens Its Core as the World Moves Toward Its Proof-Based Economy (NASDAQ: SMX)

    NEW YORK, NY / ACCESS Newswire / October 22, 2025 / Every investor knows the reflex. You see the words reverse split, and your instincts flinch. It’s practically Pavlovian. But sometimes, what looks like retreat is actually recalibration. And that’s exactly what’s happening at SMX (NASDAQ:SMX). The company that made “proof” a product and traceability a trillion-dollar opportunity just tightened its capital structure in a move that could position it for an entirely different kind of growth.

    As of October 23, 2025, SMX’s recap will take effect, consolidating approximately 15.5 million ordinary shares into about one million. The math may look surgical, but the intent is strategic. This isn’t a desperate act of survival; it’s a precision tune-up for a company that’s been quietly building the digital backbone of global commerce.

    Re-engineering the Foundation

    Let’s cut through the noise. A reverse split doesn’t change a company’s fundamentals. What it does change is perception-and for SMX, perception has always been a powerful asset. The move tightens the float, raises the share price, and signals confidence that the company’s valuation story is far from over. It’s the kind of restructuring that clears static from the air, giving the real story room to breathe.

    That story, by the way, is massive. SMX’s molecular marker technology is redefining authenticity, transforming physical goods into verifiable digital assets-proof instead of promise. Whether it’s plastics, metals, textiles, or electronics, the company’s system can permanently encode a material’s origin, lifecycle, and legitimacy.

    This isn’t theory; it’s traction. SMX’s ecosystem already includes partnerships with Singapore’s A*STAR, CETI in France, Tradepro Group, BT-Systems and REDWAVE in Europe, NAFRA and AsureQuality in Australia, and even collaborative initiatives extending into defense and critical minerals supply chains. Add to that its ongoing work with BASF and Continental, and you begin to see a network that’s not just expanding, but compounding in influence. SMX isn’t just participating in global traceability-it’s defining it.

    While others react to regulation, SMX is quietly building the infrastructure regulators will rely on. That’s not survival-it’s strategy.

    A Cap Structure Built for Momentum

    So why consolidate now? Because timing is everything. The reduction in outstanding shares creates a leaner, more investable structure-one that institutions can actually take a position in without tripping over penny-stock stigma. It’s also the first real sign that management is thinking two moves ahead, not just about survival, but about scalability.

    SMX’s balance sheet now looks like a spring-loaded platform: compact, simplified, and ready for lift. With fewer shares on the table, each incremental achievement-new project, new geography, new validation-will have a more meaningful impact on per-share value. It’s the market’s equivalent of tightening your core before the next climb.

    Proof Still Pays

    Investors who’ve been around long enough know that markets often misread these moments. They see consolidation as contraction. In reality, it’s preparation. SMX isn’t trying to look bigger; it’s getting stronger. Its partnerships are multiplying across continents, its Plastic Cycle Token is evolving into the value layer of circular commerce, and its proof-based verification model is becoming the global standard for sustainability.

    Reverse split or not, the business trajectory is unmistakable: up.

    SMX has always been about transforming invisible data into visible truth-and now, it’s doing the same with its capital structure. What investors should see isn’t a shrinking chart, but a sharpening silhouette. Because when the foundation is this strong, consolidation isn’t a warning sign. It’s the prelude to acceleration.

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements

    The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

    EMAIL: info@securitymattersltd.com

    SOURCE: SMX (Security Matters) Public Limited

    View the original press release on ACCESS Newswire

  • M42 Announces Agreement to Acquire Stake in U.S. Rare Earth and Precious Metals Company

    Companies to Leverage Innovative AI Platform to Further Define Major Shovel-Ready Metals Resource, Poised to Become One of World’s Largest Deposits

    DALLAS, TX / ACCESS Newswire / October 22, 2025 / Messier 42 LLC (“M42”), a private leading global artificial intelligence technology and digital transformation company, announces that it has entered into an agreement to acquire a minority interest in a privately developed polymetallic metal resource company based in the Western U.S., specializing in precious, rare earth and critical metals. Initial production and positive cashflow is anticipated within 12 months.

    This investment presents the opportunity to leverage M42’s successful Transformational AI platform to non-invasively locate and further define the resource company’s shovel-ready metals deposit. Both companies believe that the current NI43-101 Measured Resource Report, which is expected to be upgraded to a Probable Reserve Report based on retesting of assay results using more accurate methods, could reflect one of the world’s largest precious, critical and rare earth element deposits.

    “As the global race to secure critical and rare earth elements intensifies, we are thrilled to have found a domestic partner with a world-class resource right here on American soil-where we can apply our AI platform to further define and advance the understanding of these strategic assets,” said Michael Sandoval, Chief Scientist of M42. “By reducing reliance on foreign supply chains, this initiative directly supports American national security while positioning the United States to remain competitive in the global race for technological and economic leadership in the 21st century.”

    “This investment and partnership with M42 AI in our company strengthens U.S. capacity to secure critical minerals and rare earths-resources that are indispensable to defense systems, advanced semiconductors, renewable energy, and next-generation technologies.” said the spokesperson for the private resource company. “We look forward to working with the team at M42 AI to utilize their AI platform to advance our project.”

    The private American company has been developing their world class mine site for over 6 years and is expected to start profitable production within 12 months. In addition to producing precious metals, it is expected to mine significant grades/amounts of key critical and rare earth metals, some of which are either not produced in the US or whose supplies are imported from politically unappealing parts of the world. The management team is comprised of experienced mining and corporate developmental individuals who have successfully built this unconventional project from its inception. Ultimately, the elements contained in this discovery, will enable innovation across critical sectors of the modern U.S. economy, including semiconductors, energy, robotics, defense, and aerospace.

    The agreement is subject to certain conditions precedent and is expected to close before the end of the year.

    About M42

    M42 is a global leader in technology solutions and digital transformation, providing innovative services across various industries. As a syndicate leveraging AI for justice, truth and fairness, M42 combines deep expertise in artificial intelligence, cloud computing, and cybersecurity to drive growth and efficiency for its clients worldwide.

    Forward Looking Statements

    This document contains certain forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements, including those related to the services provided by M42 and the private resource company and the consummation of the agreement, are statements that are based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond M42’s control. Except as required by law, M42 does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

    M42 Contacts

    Matthew Selinger, Senior Partner
    Integrous Communications
    Email: mselinger@integcom.us
    Phone: 415-572-8152
    Website: https://m42.com/

    Visit us on social media:

    Facebook = https://www.facebook.com/m42ai/
    Instagram = https://www.instagram.com/m42_ai_/
    X: https://x.com/M42_AI_

    SOURCE: M42

    View the original press release on ACCESS Newswire

  • Spine Surgeon Dr. John Peloza Shared Insights on Leading a Single-Specialty ASC at Becker’s 31st Annual Meeting

    Founder of Peloza Spine joined national healthcare leaders to discuss physician-led innovation and operational excellence in orthopedic ambulatory surgery centers.

    CHICAGO, IL / ACCESS Newswire / October 22, 2025 / John H. Peloza, MD, founder of Peloza Spine in Chesterfield, Missouri, was among the featured speakers at the Becker’s 31st Annual ASC Meeting: The Business and Operations of ASCs, which took place October 16-18, 2025, at the Swissôtel Chicago. Dr. Peloza joined a distinguished panel of orthopedic leaders in the session titled “How to Lead a Single-Specialty Orthopedic ASC.”

    The discussion examined how single-specialty orthopedic ASCs have evolved beyond efficiency to become strategic hubs for growth, innovation, and physician alignment. Panelists shared insights on expanding complex case capabilities, navigating payer friction, optimizing the patient journey, and adopting technology to strengthen outcomes and sustainability.

    Drawing on his experience advancing motion-preserving spine surgery, Dr. Peloza described how surgical innovation and ASC operations needed to evolve together. He noted that the same principles driving efficiency such as team coordination, patient education, and outcome tracking were essential to supporting advanced spine procedures in an outpatient environment.

    “The ASC model has redefined how we deliver orthopedic and spine care,” said Dr. Peloza. “When physicians lead these centers, we can make nimble, data-informed decisions that enhance outcomes, expand access, and align care directly with patient needs. For spine, that means investing in teams, workflows, and technology that make motion-preserving and minimally invasive procedures truly feasible in an outpatient setting.”

    Joining Dr. Peloza on the panel were LoAnn Vande Leest, RN, MBA-H, CNOR, CASC, Executive Director of The Orthopaedic Surgery Center; Dave Fitzgerald, Chief Executive Officer of OrthoNY; and Jonathan Brown, MD, Board Member of U.S. Orthopaedic Partners and Orthopedic Surgeon at Bienville Orthopaedic Specialists. The session was moderated by Kelly Gooch, Senior Editor and Enterprise Lead at Becker’s Healthcare.

    Becker’s 31st Annual ASC Meeting brought together more than 4,000 surgery center and hospital leaders from across the United States to discuss the most pressing trends in healthcare business and operations. Sessions covered topics ranging from payer contracting and technology adoption to physician alignment and value-based care. For more information about the event, visit https://conferences.beckershospitalreview.com/31st_Annual_ASC_Meeting_2025.

    Dr. Peloza is available for interviews to discuss physician-led ASC models, motion preservation spine surgery, and the future of outpatient orthopedic care.

    About Dr. John Peloza

    Dr. John Peloza is a nationally recognized orthopedic spine surgeon with more than three decades of experience advancing motion preservation, minimally invasive spine surgery, and biologic disc repair. A prolific clinical researcher and innovator, he has served as principal investigator in 10 FDA-regulated trials and over two dozen randomized trials. Dr. Peloza holds 16 patents in spinal device and procedural technologies. Dr. Peloza is widely regarded as a pioneer in artificial disc replacement and has trained hundreds of surgeons in motion-preserving techniques. His work integrates clinical precision with a deep commitment to improving outcomes and quality of life for patients with complex spinal disorders.

    About Peloza Spine

    Peloza Spine is a specialty spine care center located within Midwest Orthopedic and Spine Specialists in Missouri, founded by Dr. John Peloza. The practice is dedicated to advancing the next generation of spinal care through a patient-centric approach that emphasizes motion preservation, surgical precision, and biologic disc regeneration. Peloza Spine provides comprehensive diagnostic services, non-operative solutions, and a full range of surgical options – including artificial disc replacement, fusion revision, and minimally invasive procedures. With a focus on restoring function and avoiding unnecessary fusion, Peloza Spine helps patients regain motion, reduce pain, and return to active living.

    Media Contact:

    Brandi Kamenar
    Brandi Kamenar Brand Management
    Email: brands@brandikamenar.com
    Phone: (310) 734-6180

    SOURCE: Peloza Spine

    View the original press release on ACCESS Newswire

  • Pajar Canada Marks 60 Years With “Zig Zag” Book Chronicling Family Legacy

    Canadian footwear company celebrates six decades as a family-run operation with the publication of a new book

    MONTRÉAL, QC / ACCESS Newswire / October 22, 2025 / Pajar Canada today announced the release of Pajar Zig Zag Book, a new volume that traces the brand’s 60-year path as a family business and its shoemaking roots dating to 1926 in Paris. The book explores the company’s “zigs and zags” through immigration, startup challenges and growth, and how a family built an enterprise kept its focus on purpose, craft, and community.

    Founded in 1963 by Paul Golbert, Pajar takes its name from the first letters of Paul, Jacques, and Rachel. The book follows the family’s immigration to Canada, the opening of the first Montreal showroom, and the launch of in-house manufacturing, while documenting how the brand built products for warmth, protection, and movement in winter conditions.

    “I grew up in this company, learning each part of the craft and sending out the daily mail orders,” said Elise Golbert, chief marketing officer at Pajar Canada and a fifth-generation shoemaker. “Zig Zag is how we tell our story, honestly, with the ups, downs, and family values that continue today.”

    Pajar Zig Zag Book highlights key milestones, including early imports of European footwear to the Canadian market, industry recognition, partnerships on the world stage, and global retail growth. It also outlines the brand’s design process, including materials, construction, and performance testing, as well as the values that continue to guide Pajar: endeavor, loyalty, and passion.

    The book connects the company’s heritage with current collections in performance footwear and outerwear, along with loungewear and cold-weather accessories, showing how the brand’s identity has stayed consistent while evolving with new materials and techniques.

    Pajar Zig Zag Book is available through Pajar Canada’s website and ships via daily mail and parcel carriers.

    For additional information about Pajar, visit and shop, and follow @PajarCanada on Instagram and Facebook and @PajarOuterwear on X (Twitter).

    About Pajar Canada
    Pajar Canada is a fifth-generation family footwear company founded in 1963 and based in Montreal, Quebec. The brand designs, manufactures, wholesales, and retails performance fashion footwear, outerwear, and accessories rooted in a rich handcrafted shoemaking heritage. Collections blend technical materials and craft to deliver warmth, protection, and comfort in cold climates. In 2023, Pajar marked its 60th anniversary with the publication of the Pajar Zig Zag Book, which documents the family’s story and design legacy. Today, the company serves customers globally through e-commerce, retail, and select partners.

    Media contact

    Name: Elise Golbert
    Email: info@pajar.com
    Phone: 1-844-932-1963
    Website: https://ca.pajar.com/

    SOURCE: Pajar Canada

    View the original press release on ACCESS Newswire